

6 Anhang

6.1 Literaturverzeichnis

1. Chu, C.Y., et al., *Fixed erythrodysesthesia plaque due to intravenous injection of docetaxel*. Br J Dermatol, 2000. **142**(4): p. 808-11.
2. Cleveland, M., B.S. Ajaikumar, and R. Reganti, *Cutaneous Fibrosis Induced by Docetaxel*. American Cancer Society, 2000. **88**: p. 1078-1081.
3. Baack, B.R. and W.H. Burgdorf, *Chemotherapy-induced acral erythema*. J Am Acad Dermatol, 1991. **24**(3): p. 457-61.
4. Battafarano, D.F., et al., *Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases*. Cancer, 1995. **76**(1): p. 110-5.
5. Comandone, A., et al., *Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment*. Anticancer Res, 1993. **13**(5C): p. 1781-3.
6. Correia, O., et al., *Nail changes secondary to docetaxel (Taxotere)*. Dermatology, 1999. **198**(3): p. 288-90.
7. Flory, S.M., et al., *Onycholysis associated with weekly administration of paclitaxel*. Ann Pharmacother, 1999. **33**(5): p. 584-6.
8. Gordon, K.B., et al., *Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy*. Cancer, 1995. **75**(8): p. 2169-73.
9. Hassett, G., P. Harnett, and N. Manolios, *Scleroderma in association with the use of docetaxel (taxotere) for breast cancer*. Clin Exp Rheumat, 2001. **19**: p. 197-200.
10. Iurlo, A., et al., *Palmar-plantar Erythrodysesthesia Syndrome Due to 5-Fluorouracil Therapy - An Underestimated Toxic Event*. Acta Oncologica, 1997. **36**(6): p. 653-654.
11. Llombart-Cussac, A., X. Pivot, and M. Spielmann, *Docetaxel chemotherapy induces transverse superficial loss of the nail plate*. Arch Dermatol, 1997. **133**(11): p. 1466-7.
12. Coates, A., F. Porzsolt, and D. Osoba, *Quality of Life in Oncology Practice: Prognostic Value of EORTC QLQ-C30 Scores in Patients with Advanced Malignancy*. Eur J Cancer, 1997. **33**(7): p. 1025-1030.

13. O'Brien, M.E., et al., *Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer*. *Ann Oncol*, 2004. **15**(3): p. 440-9.
14. Mori, T., et al., *[Possible approaches to cancer chemotherapy in palliative care medicine]*. *Gan To Kagaku Ryoho*, 2005. **32**(2): p. 156-60.
15. Houck, K., et al., *Quality of life in advanced ovarian cancer: identifying specific concerns*. *J Palliat Med*, 1999. **2**(4): p. 397-402.
16. von Plessen, C. and A. Aslaksen, *Improving the quality of palliative care for ambulatory patients with lung cancer*. *Bmj*, 2005. **330**(7503): p. 1309-13.
17. Browner, I. and M.A. Carducci, *Palliative chemotherapy: historical perspective, applications, and controversies*. *Semin Oncol*, 2005. **32**(2): p. 145-55.
18. NCI, *Common Toxicity Criteria, Version 2.0*. 1999, <http://ctep.info.nih.gov>.
19. Sehouli, J., M. David, and I. Schönborn, *Zytostatika-Extravasationen in der gynäkologischen Onkologie*. *Gynäkologische Praxis*, 1998. **22**: p. 509-519.
20. Kassner, E., *Evaluation and Treatment of Chemotherapy Extravasation Injuries*. *Journal of Pediatric Oncology Nursing*, 2000. **17**(3): p. 135-148.
21. Fitzpatrick, J.E., *The cutaneous histopathology of chemotherapeutic reactions*. *J Cutan Pathol*, 1993. **20**(1): p. 1-14.
22. Susser, W.S., D.L. Whitaker-Worth, and J.M. Grant-Kels, *Mucocutaneous reactions to chemotherapy*. *J Am Acad Dermatol*, 1999. **40**(3): p. 367-98; quiz 399-400.
23. DeSpain, J.D., *Dermatologic toxicity of chemotherapy*. *Semin Oncol*, 1992. **19**(5): p. 501-7.
24. Salzberg, M. and R. Herrmann, *Hand-foot syndrome (palmar-plantar erythrodysesthesia)*. *Schweiz Med Wochenschr*, 2000. **130**(40): p. 1413-6.
25. Ring, J., Wenning, J. Weißbuch, *Allergie in Deutschland 2000*. 2000: Deutsche Gesellschaft für Allergologie und klinische Immunologie.
26. Beyer, J., et al., *Cutaneous toxicity of high-dose carboplatin, etoposide and ifosfamide followed by autologous stem cell reinfusion*. *Bone Marrow Transplant*, 1992. **10**(6): p. 491-4.
27. Gabizon, A.A., *Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy*. *Cancer Invest*, 2001. **19**(4): p. 424-36.

28. Israel, V.P., et al., *Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers*. Gynecologic Oncology, 1999. **78**: p. 143-147.
29. Kaye, S.B., *Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer*. Semin Oncol, 1995. **22**(2 Suppl 4): p. 30-3.
30. Korac, B. and B. Buzadzic, *Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast*. J Dermatol Sci, 2001. **25**(1): p. 45-52.
31. Leo, S., et al., *Dermatological toxicity from chemotherapy containing 5-fluorouracil*. J Chemother, 1994. **6**(6): p. 423-6.
32. Link, C.J., Jr., et al., *Cutaneous manifestations of Taxol therapy*. Invest New Drugs, 1995. **13**(3): p. 261-3.
33. Lotem, M., et al., *Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin*. Arch Dermatol, 2000. **136**(12): p. 1475-80.
34. Yang, C.H., et al., *Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole*. Int J Dermatol, 2000. **39**(8): p. 621-3.
35. Wantzin, G.L. and K. Thomsen, *Acute paronychia after high-dose methotrexate therapy*. Arch Dermatol, 1983. **119**(7): p. 623-4.
36. Vanhooteghem, O., et al., *Docetaxel-induced subungual hemorrhage*. Dermatology, 1997. **194**(4): p. 419-20.
37. Pagliuca, A., R. Kaczmarek, and G.J. Mufti, *Palmar-plantar erythema associated with combination chemotherapy*. Postgrad Med J, 1990. **66**(773): p. 242-3.
38. Obermair, A., et al., *Onycholysis in patients treated with docetaxel*. Ann Oncol, 1998. **9**(2): p. 230-1.
39. Lokich, J.J. and C. Moore, *Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome*. Ann Intern Med, 1984. **101**(6): p. 798-9.
40. Brandes, A., et al., *Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine--a report of three cases*. Anticancer Drugs, 2000. **11**(1): p. 15-7.
41. Locker, G.J., et al., *Cutaneous side effects in breast cancer patients treated with cytostatic polychemotherapy and rh GM-CSF: immune phenomena or drug toxicity?* Breast Cancer Res Treat, 1995. **34**(3): p. 213-9.

42. Katz, M.E. and T.W. Hansen, *Nail plate-nail bed separation. An unusual side effect of systemic fluorouracil administration.* Arch Dermatol, 1979. **115**(7): p. 860-1.
43. Hussain, S., et al., *Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.* Cancer, 2000. **88**(10): p. 2367-71.
44. Zuehlke, R.L., *Erythematous eruption of the palms and soles associated with mitotane therapy.* Dermatologica, 1974. **148**(2): p. 90-2.
45. Jacobi, U., et al., *Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?* Ann Oncol, 2005. **16**(7): p. 1210-1.
46. Schmook, T., et al., *Detection of doxorubicin in the horny layer in a patient suffering from palmar-plantar erythrodysesthesia.* Dermatology, 2005. **210**(3): p. 237-8.
47. Lademann, J., et al., *[Penetration of microparticles into human skin].* Hautarzt, 2004. **55**(12): p. 1117-9.
48. Thigpen, J.T., et al., *Role of pegylated liposomal doxorubicin in ovarian cancer.* Gynecol Oncol, 2005. **96**(1): p. 10-8.
49. Fraser, S.C., et al., *Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.* Br J Cancer, 1993. **67**(2): p. 402-6.
50. Coates, A., et al., *On the receiving end--patient perception of the side-effects of cancer chemotherapy.* Eur J Cancer Clin Oncol, 1983. **19**(2): p. 203-8.
51. de Boer-Dennert, M., et al., *Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.* Br J Cancer, 1997. **76**(8): p. 1055-61.
52. Martin, C.G., et al., *Measuring chemotherapy-induced nausea and emesis.* Cancer, 2003. **98**(3): p. 645-55.
53. Carelle, N., et al., *Changing patient perceptions of the side effects of cancer chemotherapy.* Cancer, 2002. **95**(1): p. 155-63.
54. Hahn, C.A., et al., *Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin.* Int J Hyperthermia, 2005. **21**(4): p. 349-57.

55. Cella, D., et al., *Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane)*. *Cancer*, 2003. **98**(4): p. 822-31.
56. Augustin, M., *Erfassung von Lebensqualität in dermatologischen Studien*. *Hautarzt*, 2001. **52**(8): p. 697-700.
57. Chren, M.M., et al., *Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness*. *J Invest Dermatol*, 1996. **107**(5): p. 707-13.
58. Finlay, A.Y., *Quality of life measurement in dermatology: a practical guide*. *Br J Dermatol*, 1997. **136**(3): p. 305-14.
59. Fischer, T.W., et al., *Hairdex: a tool for evaluation of disease-specific quality of life in patients with hair diseases*. *Hautarzt*, 2001. **52**(3): p. 219-27.
60. Schafer, T., A. Staudt, and J. Ring, *Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen (DIELH)*. *Hautarzt*, 2001. **52**(7): p. 624-8.
61. Engst, R. and S. Borelli, [*Epidemiology of constitutional atopic neurodermatitis*]. *Hautarzt*, 1992. **43 Suppl 11**: p. 5-8.
62. Amantea, M., et al., *Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs*. *Hum Exp Toxicol*, 1999. **18**(1): p. 17-26.
63. Petersen, C. and K. Thomsen, *Cytostatic Agents: Effects on the Skin, Mucous Membranes, Hair and Nails*, ed. T.G.G.o. Companies. 2001. 37.
64. Essex, *Caelyx, Wissenschaftliche Produktinformationen*. 2000.
65. Essex, *Toxizitätsgrade der palmar-plantaren Erythrodysesthesie*, in *Caelyx, Zusammenfassung der Merkmale des Arzneimittels*. 2000.
66. ASCO. *ASCO 2005 Annual Meeting*. 2005 [cited 2005].
67. Lademann, J., et al., *Investigation of Doxorubicin on the skin: A spectroscopic study to understand the pathogenesis of PPE*. 2005, Charité, Universitätsmedizin Berlin.
68. Lopez, A.M., et al., *Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia*. *Cancer Chemother Pharmacol*, 1999. **44**(4): p. 303-6.
69. Vail, D.M., et al., *Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a*

- randomized, double-blind clinical trial using a canine model.* Clin Cancer Res, 1998. **4**(6): p. 1567-71.
70. Drake, R.D., et al., *Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.* Gynecol Oncol, 2004. **94**(2): p. 320-4.
71. Molpus, K.L., et al., *The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.* Gynecol Oncol, 2004. **93**(2): p. 513-6.
72. Nagore, E., A. Insa, and O. Sanmartin, *Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.* Am J Clin Dermatol, 2000. **Jul-Aug**(4): p. 225-34.
73. Charrois, G.J. and T.M. Allen, *Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.* J Pharmacol Exp Ther, 2003. **306**(3): p. 1058-67.
74. Rose, P.G., et al., *Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.* Gynecol Oncol, 2001. **82**(2): p. 323-8.
75. Lorusso, D., et al., *Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile?* Oncology, 2004. **67**(3-4): p. 243-9.
76. Lyass, O., et al., *Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.* Cancer, 2000. **89**(5): p. 1037-47.
77. Sehouli, J. and G. Oskay-Oezcelik, *Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: Results of a phase-II trial in heavily preteated patients with relapsed ovarian cancer.,* in ASCO 2004. 2004.
78. Baran, R. and L. Juhlin, *Drug-induced photo-onycholysis. Three subtypes identified in a study of 15 cases.* J Am Acad Dermatol, 1987. **17**(6): p. 1012-6.
79. Sehouli, J., G. Oskay-Oezcelik, and O. Camara, *Final Analysis of weekly Taxol (T) and weekly Carboplatin (P) as first-line Chemotherapy in 130 patients with advanced ovarian cancer (AOC),* in ASCO 2005. 2005.
80. Dean, J.C., S.E. Salmon, and K.S. Griffith, *Prevention of doxorubicin-induced hair loss with scalp hypothermia.* N Engl J Med, 1979. **301**(1427-1429).

81. Pesce, A., J.P. Cassuto, and M.V. Joyner, *Scalp tourniquet in the prevention of chemotherapy-induced alopecia*. N Engl J Med, 1978. **298**(1204-1205).
82. Aventis, *Produktmonographie Taxotere*, in *Band 1: Taxotere beim metastasierten Mammakarzinom*. 2000.
83. Muggia, F.M., et al., *Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation*. J Clin Oncol, 1997. **15**(3): p. 987-93.
84. Gordon, A.N., et al., *Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan*. J Clin Oncol, 2001. **19**(14): p. 3312-22.
85. Chan, S., et al., *Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer*. J Clin Oncol, 1999. **17**(8): p. 2341-54.
86. Nabholz, J.M., et al., *Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy*. 304 Study Group. J Clin Oncol, 1999. **17**(5): p. 1413-24.
87. Sjostrom, J., et al., *Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group*. Eur J Cancer, 1999. **35**(8): p. 1194-201.
88. Trudeau, M.E., *Docetaxel (Taxotere): an overview of first-line monotherapy*. Semin Oncol, 1995. **22**(6 Suppl 13): p. 17-21.
89. Gordon, A.N., et al., *Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer*. J Clin Oncol, 2000. **18**(17): p. 3093-100.
90. Numico, G., et al., *Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial*. Lung Cancer, 2002. **35**: p. 59-64.
91. Bullinger, M., *Gesundheitsbezogene Lebensqualität und subjektive Gesundheit. Überblick über den Stand der Forschung zu einem neuen Evaluationskriterium in der Medizin*. PPMP, 1997. **47**: p. 76-91.
92. Calman, K.C., *Quality of Life in cancer patients - hypothesis*. J Med Ethics, 1984. **10**: p. 124-127.

93. Efficace, F., et al., *Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study*. J Clin Oncol, 2004. **22**(16): p. 3381-8.
94. Maione, P., et al., *Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter italian lung cancer in the elderly study*. J Clin Oncol, 2005. **23**(28): p. 6865-72.
95. Goodwin, P.J., et al., *Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables*. J Clin Oncol, 2004. **22**(20): p. 4184-92.
96. Bottomley, A., et al., *Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study*. J Clin Oncol, 2004. **22**(13): p. 2576-86.
97. Bullinger, M., *Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine*. Psychother Psychosom Med Psychol, 1997. **47**(3-4): p. 76-91.
98. EORTC, *EORTC QLQ-C30*, in *Study Group on Quality of Life, Version 2.0*. 1995.
99. Brockfeld, T., *Epidemiologie: Aufgaben, Begriffe, Methoden*, in *Ökologisches Stoffgebiet*, T. Brockfeld, Editor. 1999, mediscript. p. 230-251.